Akebia Therapeutics (AX9) Stock Statistics & Valuation Metrics
Total Valuation
Akebia Therapeutics has a market cap or net worth of EUR 175.30M. The enterprise value is EUR 360.90M.
- Market Cap
- EUR 175.30M
- Enterprise Value
- EUR 360.90M
Share Statistics
Akebia Therapeutics has 277,106,230 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 277,106,230
- Owned by Insiders
- 2.89%
- Owned by Institutions
- 20.18%
Financial Efficiency
Akebia Therapeutics’s return on equity (ROE) is -0.16 and return on invested capital (ROIC) is 9.26%.
- Return on Equity (ROE)
- -0.16
- Return on Assets (ROA)
- -0.01
- Return on Invested Capital (ROIC)
- 9.26%
- Return on Capital Employed (ROCE)
- 0.11
- Revenue Per Employee
- 1.22M
- Profits Per Employee
- -27.55K
- Employee Count
- 194
- Asset Turnover
- 0.63
- Inventory Turnover
- 2.53
Valuation Ratios
The current PE Ratio of Akebia Therapeutics is -6.54. Akebia Therapeutics’s PEG ratio is 0.01.
- PE Ratio
- -6.54
- PS Ratio
- 0.89
- PB Ratio
- 7.61
- Price to FCF
- 4.87
- Price to Operating Cash Flow
- 4.58
- PEG Ratio
- 0.01
Income Statement
In the last 12 months, Akebia Therapeutics had revenue of 236.20M and earned -5.34M in profits. Earnings per share was -0.02.
- Revenue
- 236.20M
- Gross Profit
- 196.73M
- Operating Income
- 23.50M
- Pretax Income
- -3.72M
- Net Income
- -5.34M
- EBITDA
- 21.73M
- Earnings Per Share (EPS)
- -0.02
Cash Flow
In the last 12 months, operating cash flow was 41.55M and capital expenditures -1.38M, giving a free cash flow of 40.23M billion.
- Operating Cash Flow
- 41.55M
- Free Cash Flow
- 40.23M
- Free Cash Flow per Share
- 0.15
Dividends & Yields
Akebia Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 20.55%
- Earnings Yield
- -15.57%
Stock Price Statistics
- Beta
- 1.09
- 52-Week Price Change
- -63.22%
- 50-Day Moving Average
- 0.73
- 200-Day Moving Average
- 0.97
- Relative Strength Index (RSI)
- 48.63
- Average Volume (3m)
- ―
Important Dates
Akebia Therapeutics upcoming earnings date is Nov 05, 2026, Before Open (Not Confirmed).
- Last Earnings Date
- Aug 05, 2026
- Next Earnings Date
- Nov 05, 2026
- Ex-Dividend Date
- ―
Financial Position
Akebia Therapeutics as a current ratio of 1.13, with Debt / Equity ratio of 663.29%
- Current Ratio
- 1.13
- Quick Ratio
- 1.04
- Debt to Market Cap
- 0.52
- Net Debt to EBITDA
- 1.45
- Interest Coverage Ratio
- 0.97
Taxes
In the past 12 months, Akebia Therapeutics has paid 1.62M in taxes.
- Income Tax
- 1.62M
- Effective Tax Rate
- -0.44
Enterprise Valuation
Akebia Therapeutics EV to EBITDA ratio is -5.14, with an EV/FCF ratio of 2.34.
- EV to Sales
- 0.43
- EV to EBITDA
- -5.14
- EV to Free Cash Flow
- 2.34
- EV to Operating Cash Flow
- 2.27
Balance Sheet
Akebia Therapeutics has EUR 155.55M in cash and marketable securities with EUR 53.96M in debt, giving a net cash position of EUR 101.58M billion.
- Cash & Marketable Securities
- EUR 155.55M
- Total Debt
- EUR 53.96M
- Net Cash
- EUR 101.58M
- Net Cash Per Share
- EUR 0.37
- Tangible Book Value Per Share
- -EUR 0.13
Margins
Gross margin is 79.48%, with operating margin of -6.91%, and net profit margin of -13.54%.
- Gross Margin
- 79.48%
- Operating Margin
- -6.91%
- Pretax Margin
- -12.71%
- Net Profit Margin
- -13.54%
- EBITDA Margin
- -8.37%
- EBIT Margin
- -9.08%
Analyst Forecast
The average price target for Akebia Therapeutics is EUR 3.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 3.50
- Price Target Upside
- 440.56% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 5
- Revenue Growth Forecast
- 0.30%
- EPS Growth Forecast
- 40.06%
Scores
- Smart Score
- 4
- AI Score
- ―
